• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Mural Oncology plc

    6/26/25 5:26:13 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Mural Oncology plc

    (Name of Issuer)


    Ordinary Shares, nominal value $0.01 per share

    (Title of Class of Securities)


    G63365103

    (CUSIP Number)


    06/23/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G63365103


    1Names of Reporting Persons

    Prosight Management, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    900,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    900,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    900,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 17,268,881 Ordinary Shares, nominal value $0.01 per share ("Ordinary Shares") of Mural Oncology plc (the "Issuer") outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    G63365103


    1Names of Reporting Persons

    Prosight Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    51,390.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    51,390.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    51,390.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    G63365103


    1Names of Reporting Persons

    Prosight Plus Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    196,625.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    196,625.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    196,625.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    G63365103


    1Names of Reporting Persons

    Prosight Partners, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    900,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    900,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    900,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    G63365103


    1Names of Reporting Persons

    W. Lawrence Hawkins
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    900,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    900,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    900,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Mural Oncology plc
    (b)Address of issuer's principal executive offices:

    10 Earlsfort Terrace, Dublin 2, Ireland, D02 T380
    Item 2. 
    (a)Name of person filing:

    This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership ("Prosight Management"), Prosight Fund, LP, a Delaware limited partnership ("Prosight Fund"), Prosight Plus Fund, LP, a Delaware limited partnership ("Prosight Plus Fund"), Prosight Partners, LLC, a Delaware limited liability company ("Prosight Partners"), and W. Lawrence Hawkins (collectively referred herein as the "Reporting Persons"). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the "Managed Accounts") and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners. Prosight Fund, Prosight Plus Fund, and the Managed Accounts are the record and direct beneficial owner of the securities of the Issuer covered by this statement. Prosight Fund disclaims beneficial ownership of the securities of the Issuer held by each of the Managed Accounts and Prosight Plus Fund. Prosight Plus Fund disclaims beneficial ownership of the securities of the Issuer held by each of the Managed Accounts and Prosight Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto.
    (d)Title of class of securities:

    Ordinary Shares, nominal value $0.01 per share
    (e)CUSIP No.:

    G63365103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 on the cover pages hereto.
    (b)Percent of class:

    See Item 11 on the cover pages hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover pages hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover pages hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover pages hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover pages hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Prosight Management, LP
     
    Signature:Prosight Partners, LLC
    Name/Title:General Partner
    Date:06/26/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner
    Date:06/26/2025
     
    Prosight Fund, LP
     
    Signature:Prosight Management, LP
    Name/Title:General Partner
    Date:06/26/2025
     
    Signature:Prosight Partners, LLC
    Name/Title:Sole Manager of the General Partner
    Date:06/26/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner of the General Partner
    Date:06/26/2025
     
    Prosight Plus Fund, LP
     
    Signature:Prosight Management, LP
    Name/Title:General Partner
    Date:06/26/2025
     
    Signature:Prosight Partners, LLC
    Name/Title:General Partner of the General Partner
    Date:06/26/2025
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager of the General Partner of the General Partner
    Date:06/26/2025
     
    Prosight Partners, LLC
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:Sole Manager
    Date:06/26/2025
     
    W. Lawrence Hawkins
     
    Signature:/s/ W. Lawrence Hawkins
    Name/Title:W. Lawrence Hawkins
    Date:06/26/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement (filed herewith).

    Get the next $MURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURA

    DatePrice TargetRatingAnalyst
    3/25/2025Overweight → Equal-Weight
    Morgan Stanley
    3/25/2025$18.00Strong Buy → Outperform
    Raymond James
    6/28/2024$15.00Buy
    Rodman & Renshaw
    4/4/2024$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $MURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Altschuller Susan bought $32,071 worth of Ordinary Shares (10,000 units at $3.21) (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    8/15/24 4:15:04 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

    WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

    8/20/25 8:30:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

    Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead product candidate, nemvaleukin alfa, and was commencing the exploration of strategic alternatives focused on maximizing shareholder value. The Company is continuing to explore

    8/4/25 8:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Plans to Explore Strategic Alternatives

    Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer

    4/15/25 8:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mural Oncology downgraded by Morgan Stanley

    Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

    3/25/25 12:58:54 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Raymond James with a new price target

    Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

    3/25/25 11:43:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Mural Oncology with a new price target

    Rodman & Renshaw initiated coverage of Mural Oncology with a rating of Buy and set a new price target of $15.00

    6/28/24 8:19:17 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Mural Oncology plc

    DEFA14A - Mural Oncology plc (0001971543) (Filer)

    8/20/25 8:53:25 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology plc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Mural Oncology plc (0001971543) (Filer)

    8/20/25 8:50:42 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc

    SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

    8/14/25 9:17:31 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Keson-Brookes Maiken sold $6,379 worth of Ordinary Shares (2,572 units at $2.48), decreasing direct ownership by 4% to 68,834 units (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    7/23/25 5:00:40 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Keson-Brookes Maiken sold $5,352 worth of Ordinary Shares (2,158 units at $2.48), decreasing direct ownership by 3% to 71,406 units (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    7/22/25 5:00:05 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Loew Caroline sold $30,475 worth of Ordinary Shares (12,531 units at $2.43), decreasing direct ownership by 4% to 293,059 units (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    7/9/25 5:00:03 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Leadership Updates

    Live Leadership Updates

    View All

    Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

    Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

    11/13/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

    Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

    9/26/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

    WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

    9/23/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/14/24 5:15:53 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/12/24 3:52:44 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/4/24 2:39:13 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    Financials

    Live finance-specific insights

    View All

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

    WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

    8/20/25 8:30:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

    Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead product candidate, nemvaleukin alfa, and was commencing the exploration of strategic alternatives focused on maximizing shareholder value. The Company is continuing to explore

    8/4/25 8:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

    Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 2025 Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin alfa in the ARTISTRY-6 trial in patients with cutaneous melanoma expected in 1H 2025 for monotherapy (cohort 3) and 2H 2025 for combination therapy (cohort 4) Cash runway extended into Q1 2026 through operational efficiencies WALTHAM, Mass. and DUBLIN, March 11, 2025 (GLOBE NEWSWIRE) -- Mural Oncolog

    3/11/25 4:01:00 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care